Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Lymphoma, Follicular
  • Lymphoma, Non-Hodgkin
  • Neoplasm Recurrence, Local
  • Radioimmunotherapy

abstract

  • The tositumomab and iodine-131 tositumomab therapeutic regimen produces high response rates in patients with relapsed or refractory low-grade, follicular, and transformed low-grade NHL, with a sizable subgroup of patients achieving long-term durable responses.

publication date

  • December 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2004.00.9217

PubMed ID

  • 16186600

Additional Document Info

start page

  • 7565

end page

  • 73

volume

  • 23

number

  • 30